Introduction: AYUSH 82 powder is an Ayurvedic antidiabetic formulation developed by the Central Council for Research in Ayurvedic Sciences (CCRAS), Ministry of AYUSH, Govern ment of India. The antidiabetic potential of AYUSH 82 powder along with its two new dosage forms-AYUSH 82 mixture extract and AYUSH 82 compound extract-has been established to be mediated via α-amylase inhibitory property, insulin-dependent glucose uptake in skeletal muscle cell line (C2C12 myotubes).
INTRODUCTION
Type II diabetes mellitus (DM) is a chronic metabolic disorder whose global prevalence has been increasing steadily. As such, it is on the verge of becoming an epidemic in some countries. The number of people affected by DM is expected to double in the next decade, thereby adding to the already existing burden for health care providers, especially in poorly developed countries. 1 Diabetes mellitus is diagnosed based on sustained hyperglycemia. People with DM are at elevated risk for a number of serious health problems, including cardiovascular disease, premature death, blindness, kidney failure, amputations, fractures, frailty, depression, and cognitive decline. 2 
AYUSH 82
is an Ayurvedic formulation for diabetes developed by the CCRAS, Ministry of AYUSH, Government of India. It comprises ingredients traditionally used for their beneficial effect in diabetes (Prameha/Madhumeha). 3 Glucose-lowering effects of AYUSH 82 powder have been reported in patients of Madhumeha where AYUSH 82 powder (5 gm TDS with 500 mg of pure Shilajit BD for 24 weeks) was found to significantly reduce fasting and postprandial blood sugar levels along with clinical improvement in diabetic subjects. 4 In another clinical study, AYUSH 82 administered at similar doses to patients of noninsulin-dependent DM was found to produce significant reduction (p > 0.001) in both fasting and postprandial blood sugar and also showed marked improvement in symptoms of diabetes like polyuria, polydipsia, polyphagia, weakness, and exhaustion after a treatment period of 6 weeks. 5 The antidiabetic potential of AYUSH 82 powder along with its two new dosage forms-mixture extract and compound extract when investigated in vitro through mechanism of their action exhibited inhibition of α-amylase activity and an increase in insulin-dependent glucose uptake in C2C12 myotubes as compared with control. 6 In the current study, we investigated the in vivo antidiabetic potential of AYUSH 82 mixture in comparison to AYUSH 82 mixture extract with Shilajit. The study was conducted in streptozotocin (STZ)-induced type II diabetic rat model.
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MATERIALS AND METHODS
Chemicals/Reagent/Media
Streptozotocin (Sigma), metformin hydrochloride I.P-500 mg (Cipla), Mercer Expert Assay rat insulin enzymelinked immunosorbent assay (ELISA) kit.
Preparation of AYUSH 82 Mixture Extract and AYUSH 82 Mixture Extract + Shuddh Shilajit
For AYUSH 82 mixture extract (DRDC/2016/008): Hydroalcoholic extraction of equal quantities of individual herbs (Karavellaka, Jamun, Amra, and Gurmar) was done and then mixed together. The extract was concentrated and dried to fine powder, which was checked for compliance with specification parameters (Table 1) . For AYUSH 82 mixture extract + Shuddh Shilajit (DRDC/2016/009): Hydroalcoholic extraction of equal quantities of individual herbs (Karavellaka, Jamun, Amra, and Gurmar) were taken and then mixed together along with Shuddh Shilajit. The extract was concentrated and dried to fine powder, which was checked for compliance with specification parameters.
Experimental Animals
Male Sprague Dawley rats (3-5 days old) weighing 7 to 10 gm were housed under standard laboratory conditions of target room temperature: 22 ± 3°C, target relative humidity: 30 to 70%, light/dark cycle: 12-hourly, feed: conventional feed purchased from a commercial supplier were provided in fixed amount to the animals. Water: filtered drinking water ad libitum. The experimental procedures were conducted after the approval of Ethical Committee-CPCSEA, dated April 18, 2016 with approval No. IAEC/37/422, Ministry of Environment and Forest, Government of India.
Antidiabetic Activity
STZ-induced Sprague Dawley Rat Model for DM
Preparation of STZ Solution: Aliquots of STZ (Sigma) 10 mg were weighed and covered with aluminum foils to protect from light. The STZ aliquots were dissolved in freshly prepared ice cold 0.1 M citrate buffer, pH 4.5, and were used within 15 minutes.
Induction of Diabetes: Male Sprague Dawley pups (n = 40) were administered with intraperitoneal injection of a freshly prepared STZ at the dose of 80 mg/kg in an ice-cold 0.1 M citrate buffer (pH 4.5). Rat pups (n = 8) in nondiabetic control group were administered with citrate buffer.
Experimental Design
Randomization: After weaning off STZ injection (day 21), the animals were kept in groups of five in collective cages, with a full access to food and water for the following 8 weeks.
Eight weeks postinjection, diabetic animals were randomized into four groups containing eight animals in each group based on the oral glucose tolerance test (OGTT) which was carried out at 0, 30, and 90 minutes. Based on insulin resistance, the animals were selected and grouped. For OGTT, animals were fasted for 16 hours. Basal blood glucose levels (BGL) were estimated at 0 minute. All the animals including those in normal control group were administered orally with glucose at the dose of 2 gm/kg by gavage. The BGL were estimated at 30 and 90 minutes, postglucose administration. The BGL values at various time points were subjected for GAUC 0 to 90 calculation by WinNonlin software. Based on the results of OGTT, randomization was done in which 32 animals were divided into four groups, each consisting of eight animals as follows: Dosing: Dosing was initiated on day 1 evening and finished on day 29 morning to complete the 28 days twicedaily dosing regimen. Body weight, feed intake, and clinical signs were measured daily throughout the study period. BGL was measured weekly. On day 29, OGTT was repeated. At the end of the treatment period (day 29), blood was collected from rats by retro-orbital puncture and centrifuged. Serum was separated for estimation of glucose and lipid profile (triglyceride and cholesterol). Serum insulin also was estimated using commercially available ELISA kit. Thereafter, animals were humanely sacrificed; pancreas was collected, weighed, and preserved in 10% buffered formalin for histopathological (hematoxylin and eosin staining) investigation.
RESULTS
Clinical Signs and Observation
Daily cage-side observations were made to detect clinical signs and mortality from the day of dosing till end of the study. No clinical signs of toxicity were found during experimental period.
Body Weight
Body weight of all the animals was recorded from day 1 to day 28. The percent change in body weight for each animal was calculated. Decreasing trend in percent body weight change was observed in diabetic control rats from day 7 to 28 as compared with normal control. No significant difference in percent bodyweight change was observed among the treatment groups as compared with diabetic control.
Feed Intake
During the study (d2-28), the mean of cumulative feed consumption was lower in disease control as compared with normal control. However, no significant difference in cumulative feed consumption was observed among the treatment groups as compared with diabetic control.
Blood Glucose
Fed BGLs were measured weekly (day 1, 7, 14, 21, 28, and 29) by using Glucose Meter Contours™ TS. Mean fed BGL and percent change in blood glucose with respect to diabetic control was calculated for each group.
Mean Fed
There was significant increase in BGL for (G2) diabetic control animals, which was 145.35 mg/dL as compared with normal control (G1) animals whose mean BGL was 109.36 mg/dL on day 29. This increase in fed BGL in diabetic control animals (G2) was observed throughout the study. AYUSH 82 mixture extract (G3) treatment showed 10.69% reduction in fed BGL on day 29 when compared with diabetic control (G2). Animals treated with AYUSH 82 mixture extract + Shuddh Shilajit showed 5.62% reduction on day 29. Metformin 250 mg/kg-treated rats have shown 4.72% reduction in fed BGL on day 29. However, there was no statistical significant difference between the groups (Graph 1).
Glucose Tolerance Test
Significant increase (p < 0. 
Biochemical Parameters
Increase in triglyceride level and decrease in cholesterol level were observed in disease control compared with normal control. The triglyceride levels in AYUSH 82 mixture extract (G3)-treated animals were 23.45% lower than those in diabetic control. AYUSH 82 mixture + Shuddh Shilajit-treated animals showed 10.87 and 11.26% decrease in cholesterol and triglycerides level respectively. In metformin-treated rats (G5), 22.52% reduction in mean triglyceride level and 6.17% reduction in mean cholesterol levels were observed compared with diabetic control (Graphs 3 and 4).
Insulin Levels
In AYUSH 82 mixture extract (G3)-treated rats, 25.83% increase in insulin level was observed as compared with diabetic control, which is statistically significant. AYUSH 82 mixture extract + Shuddh Shilajit treatment (G4) resulted in 9.61% increase in insulin level and metformin 250 mg/kg (G5)-treated rats showed 8.31% increase in insulin levels compared with diabetic control (G2) group animals (Graph 5).
Pancreas Weight
Decrease in pancreas weight was observed in disease control as compared with normal control. No significant difference in relative pancreas weight was observed among the treatment groups as compared with diabetic control.
Histopathology
On day 29, the rats were euthanized and the pancreas from all rats was collected for histology study. Mean
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Graph 1: Percentage change in fed BGL
reduced mean β-cell number, size, and markedly degenerated pancreatic islets as compared with normal control. AYUSH 82 mixture extract (G3) group had marginal effect, i.e., 9.9% improvement in histopathological grading of various histological parameters as compared with diabetic control, which indicated tendency of protecting the islets from progressive damage due to STZ during the 28-day study period. However, 8.3% improvement in histopathological grading was observed in AYUSH 82 mixture extract + Shuddh Shilajit (G4) group animals. Metformin-treated rats showed 13.2% improvement in severity of histopathological lesions (Fig. 1) .
DISCUSSION
In vitro and in vivo study results suggested that AYUSH 82 mixture extract has antidiabetic potential which may be due to the ingredients present in the formulation like Jambu, Karavellaka, Amra, and Gurmar. The published literature available also supports the antidiabetic action of the individual herbs of the formulation. In one of the published studies, the effects of powder and ethanol extract of S. cumini (Jambu) seeds (1.25 per kg body weight) treatment for 21 days on glucose homeostasis, serum insulin, serum lipids, and liver glycogen content in STZ-induced type II diabetic rats were evaluated. The administration of S. cumini seed powder and ethanol extract for 21 days to type II diabetic rats significantly reduced the fasting glucose level, although it did not alter the BGL after glucose challenge. The insulin level and liver glycogen content were also not changed after dietary administration of S. cumini seed powder or ethanol extract. In addition to hypoglycemic effect, the S. cumini significantly ameliorated the lipid profile. The plasma low-density lipoprotein-cholesterol level, an atherogenic lipid, significantly (p < 0.01) decreased with a concurrent increase (p < 0.01) in the plasma high-density lipoproteincholesterol level, thus suggesting dietary S. cumini could be used as one of the alternatives in the treatment of diabetes. 7 Methanol extract of G. sylvestre (Gurmar) leaf and callus showed antidiabetic activities through regenerating β-cells in treated rats, when compared with the standard diabetic rats. 8 Dihydroxy gymnemic triacetate from G.
sylvestre at 20 mg dose produced significant effects on all biochemical parameters studied compared with diabetic control group. 9 The treatment of diabetic rats with M. charantia (Karavellaka) fruit extract over a 10-week period returned these levels close to normal. In addition, M. charantia juice also exhibited an inhibitory effect on membrane lipid peroxidation under in vitro conditions. These results suggest that M. charantia fruit extract exhibits hypolipidemic as well as hypoglycemic effects in the STZinduced diabetic rat. 10 The alcoholic extract of M. indica (Amra) leaves and kernel seeds are reported to possess significant antidiabetic effect against alloxan-induced diabetes in Wistar rats and its stimulating insulin production in pancreas of Wistar rats. 11 Previously, in vitro studies on the various tested dosage forms of AYUSH 82 powder, mixture extract, and the compound extract have shown antidiabetic activity mediated either through inhibition of α-amylase activity or regulation of insulin -dependent glucose uptake in mouse skeletal cell line.
6
CONCLUSION
Oral administration of AYUSH 82 mixture extract twice daily for 28 days to STZ-induced Sprague Dawley rats showed significant increase in serum insulin levels, reduction in GAUC 0-90 , fed BGL, and triglyceride levels. It also showed improvement in histopathological grading, which resulted in protecting the pancreatic islets from progressive damage.
No statistical difference was observed in any of the treated groups (AYUSH 82 mixture extract, AYUSH 82 mixture extract + Shilajit or metformin group) in any of the biochemical parameters related to diabetes. However, statistically significant improvement in parameters related to diabetes was observed in treated groups as compared with untreated control diabetic rats.
Based on the above results, it can be concluded that AYUSH 82 mixture extract has antidiabetic potential. Addition of Shilajit to AYUSH 82 mixture extract did not contribute to much improvement in biochemical parameters related to diabetes.
